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Abstract
 
Vascular endothelial growth factor (VEGF) C and VEGF-D stimulate lymphangiogenesis and
angiogenesis in tissues and tumors by activating the endothelial cell surface receptor tyrosine
kinases VEGF receptor (VEGFR) 2 and VEGFR-3. These growth factors are secreted as
full-length inactive forms consisting of NH
 
2
 
- and COOH-terminal propeptides and a central
VEGF homology domain (VHD) containing receptor binding sites. Proteolytic cleavage
removes the propeptides to generate mature forms, consisting of dimers of the VEGF homology
domain, that bind receptors with much greater affinity than the full-length forms. Therefore,
proteolytic processing activates VEGF-C and VEGF-D, although the proteases involved were
unknown. Here, we report that the serine protease plasmin cleaved both propeptides from the
VEGF homology domain of human VEGF-D and thereby generated a mature form exhibiting
greatly enhanced binding and cross-linking of VEGFR-2 and VEGFR-3 in comparison to full-
length material. Plasmin also activated VEGF-C. As lymphangiogenic growth factors promote
the metastatic spread of cancer via the lymphatics, the proteolytic activation of these molecules
represents a potential target for antimetastatic agents. Identification of an enzyme that activates
the lymphangiogenic growth factors will facilitate development of inhibitors of metastasis.
Key words: lymphangiogenesis • lymphatics • angiogenesis • proteolysis • metastasis
 
Introduction
 
Vascular endothelial growth factor (VEGF) C and VEGF-D
are secreted glycoproteins that induce angiogenesis and lym-
phangiogenesis. For example, overexpression of VEGF-C or
VEGF-D in the skin of transgenic mice resulted in lymphatic
hyperplasia (1, 2), and adenoviral delivery of VEGF-D in
adult tissues induced tissue-specific angiogenesis and lym-
phangiogenesis (3). Lymphangiogenic growth factors show
promise for enhancing tissue fluid drainage for treatment of
lymphedema (4, 5). In cancer models, expression of VEGF-C
or VEGF-D stimulated growth of tumor lymphatics and,
importantly, promoted metastasis via lymphatic vessels (6, 7).
Clinical analyses revealed that expression of VEGF-C or
VEGF-D in breast, ovarian, and colorectal cancer may be a
prognostic indicator associated with lymph node metastasis
(8–11). These findings indicate that inhibitors of VEGF-C
and VEGF-D may be useful as anticancer agents designed to
block metastatic spread, as illustrated by use of a neutralizing
VEGF-D antibody to block metastasis via the lymphatics in a
mouse model of cancer (7).
The effects of VEGF-C and VEGF-D are mediated by
VEGF receptor (VEGFR) 2 and VEGFR-3 (12, 13), cell
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surface receptor tyrosine kinases predominantly expressed on
endothelial cells (for review see reference 14). VEGFR-2 is
expressed on blood vessels during embryogenesis and is criti-
cal for early vasculogenesis and angiogenesis (14). It can be
up-regulated on adult blood vessels in cancer and is thought
to signal for tumor angiogenesis (14). VEGFR-3 is initially
expressed on the endothelium of blood vessels during em-
bryogenesis and is critical for formation of large vessels in the
early embryo (15). In the adult, VEGFR-3 is predominantly
restricted to lymphatic endothelium (14), where activation
of this receptor induces lymphangiogenesis (2). However,
VEGFR-3 can be up-regulated on the endothelium of blood
vessels in tumors (14) and during wound healing (16).
VEGF-C and VEGF-D are initially synthesized as full-
length forms consisting of NH
 
2
 
- and COOH-terminal
propeptides flanking the central VEGF homology domain
(VHD) that contains the receptor binding sites (13, 17). Pro-
teolytic processing results in cleavage of the propeptides from
the VHD, generating mature VHD homodimers that bind
VEGFR-2 and VEGFR-3 with much higher affinity than
the full-length form (17, 18). Hence, proteolytic processing
activates the lymphangiogenic growth factors but the pro-
teases involved were unknown. Here, we describe an ap-
proach for detecting the proteolytic processing of VEGF-D
with which we identified the serine protease plasmin as an
activator of VEGF-D. Plasmin generated mature, bioactive
VEGF-D from full-length material, and also activated
 
VEGF-C. This is the first identification of an enzyme capa-
ble of fully activating lymphangiogenic growth factors.
 
Materials and Methods
 
Peptide Labeling. 
 
1 mg of biotinylated peptide (Auspep) in
200 
 
 
 
l of 200 mM 2-morpholinoethane sulfonic acid (MES), pH
6.0, was mixed with 455 
 
 
 
Ci [
 
3
 
H]N-ethylmaleimide (NEM) in
pentane (PerkinElmer) and pentane removed under N
 
2
 
. After in-
cubation at room temperature for 10 min, 50 
 
 
 
g NEM in 200
mM MES, pH 6.0, was added and incubated for 1 h at room
temperature. An additional 500 
 
 
 
g NEM in 200 mM MES, pH
6.0, was added and incubated for 1 h at room temperature. La-
beled peptide was separated from unincorporated label by chro-
matography on Sephadex G-10 in 150 mM NaCl.
 
Purification of VEGF-C and VEGF-D. 
 
VEGF-C-FULL-N-
FLAG or VEGF-D-FULL-N-FLAG (full-length human VEGF-C
or VEGF-D tagged at the NH
 
2
 
 terminus with the FLAG oc-
tapeptide), VEGF-D
 
 
 
N
 
 
 
C-FLAG (the VHD of human VEGF-D
tagged at the NH
 
2
 
 terminus with FLAG; reference 18) and mouse
VEGF-D
 
326
 
-FLAG and VEGF-D
 
358
 
-FLAG (full-length isoforms
tagged at the COOH termini with FLAG; reference 19) were pu-
rified from the conditioned media of transfected 293EBNA cells
as described previously (18).
 
Protease Digests. 
 
Protease digestions were in 10 mM potassium
phosphate buffer, pH 7.5, 150 mM NaCl at 37
 
 
 
C for 1 h. Digests
contained between 10 and 10
 
 
 
2
 
 U/ml of plasmin from human se-
rum (Calbiochem). 
 
 
 
2-antiplasmin (Calbiochem) was incubated
with plasmin in PBS for 30 min at room temperature before addi-
Figure 1. Scintillation proximity
assay. (a) Sequence of the peptide
encompassing the site at which the
VHD of VEGF-D is cleaved from
the COOH-terminal propeptide
(C-pro). In VEGF-D from 293EBNA
cells, cleavage occurs between argi-
nine 205 and serine 206 (arrowhead;
reference 18). Numbers above the
amino acid sequence denote posi-
tions in human VEGF-D (13). The
COOH-terminal cysteine residue,
not found in VEGF-D, facilitated
radiolabeling. (b) Principle of SPA.
Black bars represent biotinylated (B),
tritiated VEGF-D peptide that is
treated with proteases, and bound to
streptavidin-conjugated scintillant
beads before   counting. SB denotes
scintillant beads and open brackets
denote streptavidin moieties conju-
gated to the beads. (c) SPA results
after treatment of VEGF-D peptide
with proteases. Values are the aver-
age of three replicates   1 SD and
are representative of duplicate exper-
iments. P-values comparing plasmin-
or thrombin-treated samples with
negative control were calculated
using Student’s t test. Negative
control is undigested peptide. (d) Mass
spectrometric analysis of VEGF-D
peptide before (top) and after plas-
min digestion (bottom). Identity of
the major peak in each panel is
shown.T
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tion of VEGF-D-FULL-N-FLAG and digestion at 37
 
 
 
C for 1 h.
Digests with tissue plasminogen activator (Calbiochem) contained
0.5–50 kU/ml of enzyme. Scintillation proximity assays contained
0.1 U/ml plasmin, 0.1 U/ml thrombin, 5 mU/ml matrix metallo-
proteinase (MMP) 2, or 9 mU/ml MMP-9 (Calbiochem).
 
Scintillation Proximity Assay. 
 
After incubation with pro-
teases, 10
 
4
 
 cpm of labeled biotinylated peptide was mixed with
200 mg streptavidin scintillant beads (Amersham Biosciences) in
10 mM potassium phosphate buffer, pH 6.0, at room temperature
for 20 min, before 
 
 
 
 counting.
 
Western Blotting. 
 
After SDS-PAGE and transfer to mem-
branes, proteins were probed with biotinylated antibody to the
VHD of mouse VEGF-D (R&D Systems) and HRP-conjugated
streptavidin (Zymed Laboratories) and developed using chemilu-
minescence (Pierce Chemical Co.).
 
Amino Acid Sequencing. 
 
NH
 
2
 
-terminal amino acid sequenc-
ing was with a biphasic NH
 
2
 
-terminal protein sequencer (model
G1005A; Agilent Technologies).
 
Mass Spectrometry. 
 
Peptides were desalted using 
 
 
 
C
 
18
 
 ZipTips
(Millipore) and cocrystallized onto a 10 
 
 
 
 10 matrix-assisted laser
desorption/ionization stainless steel sample plate (Applied Biosys-
tems) with 2,5-dihydroxy benzoic acid matrix (Agilent Technolo-
gies) in 0.1% TFA/60% acetonitrile and dried for 10 min. Samples
were analyzed on the o-matrix-assisted laser desorption/ionization
QStar™ Pulsar mass spectrometer (Applied Biosystems). Positive
TOF MS was collected from 700 to 3,000 D for 1 min.
 
Assays of Receptor Binding and Cross-linking. 
 
Binding assays
with VEGF-D-FULL-N-FLAG and soluble receptor-Ig fusion
proteins containing the extracellular domains of human VEGFR-2
or VEGFR-3 and the Fc portion of human IgG
 
1
 
 (provided by Y.
Gunji, Haartman Institute, Helsinki, Finland and K. Pajusola,
Biotechnology Institute, Helsinki, Finland respectively) were per-
formed as described previously, as were bioassays with Ba/F3 cells
and ligands at 750 ng/ml (13).
 
Results
 
Assay for VEGF-D Processing. 
 
To identify proteases that
activate VEGF-D, a scintillation proximity assay (SPA) was
developed for monitoring cleavage of the COOH-terminal
propeptide from the VHD. The assay was based on the
COOH-terminal cleavage because this occurs at a single site
in VEGF-D, whereas cleavage of the NH
 
2
 
-terminal propep-
tide is more complex, occurring at two distinct sites (18). For
the assay, a 17-mer peptide (containing residues 198–213 of
human VEGF-D) spanning the COOH-terminal cleavage
 
site of VEGF-D, was biotinylated at its NH
 
2
 
 terminus and
radiolabeled at its COOH terminus (Fig. 1 a). The principle
of the SPA is outlined in Fig. 1 b. After the peptide is treated
with proteases, it is bound to streptavidin-conjugated beads
impregnated with scintillant. When the peptide is intact, the
proximity of the radiolabel at the COOH terminus of the
peptide to the scintillant in the beads is sufficient to generate
detectable photons. In contrast, there is a dramatic reduction
in counts detected when cleavage of the peptide has oc-
curred because the radiolabel is no longer sufficiently close to
the scintillant for photons to be generated.
A range of proteases were tested in this assay, including
plasmin, thrombin, and MMP-2 and MMP-9. These pro-
teases were chosen because of their involvement in angio-
genesis or tumor formation. MMP-2 and MMP-9 had no
effect on the counts detected in the SPA, however, plasmin
caused a 
 
 
 
90% reduction of signal, indicating substantial
cleavage of the peptide (Fig. 1 c). Thrombin caused a small
reduction of signal. To identify the site at which plasmin hy-
drolyzed the peptide, samples were analyzed by mass spec-
trometry. Undigested peptide consisted of a single peak of a
molecular mass of 2,282.15 kD, as expected (Fig. 1 d, top).
After plasmin treatment, a predominant peak of a molecular
mass of 1,267.68 kD was observed, corresponding to Biotin-
HPYSIIRR (Fig. 1 d, bottom). This molecular species is an
expected product of cleavage of the peptide at the same site
as observed in VEGF-D expressed in 293EBNA cells (i.e.,
between R205 and S206) (Fig. 1 a; reference 18). An alter-
native cleavage event generating Biotin-HPYSIIR (molecu-
lar mass 1,111.59 kD) was also detected.
 
Plasmin Processes VEGF-D. 
 
To establish if VEGF-D is
a substrate for plasmin, this protease was incubated with
full-length human VEGF-D (VEGF-D-FULL-N-FLAG)
purified from the medium of transfected 293EBNA cells.
A degree of proteolytic processing occurs in the medium
of these cells, resulting in VEGF-D preparations contain-
ing full-length material (
 
 
 
50 kD) and a partially pro-
cessed form (
 
 
 
31 kD) consisting of the NH
 
2
 
-terminal
propeptide and VHD (Fig. 2 a; reference 18). After plas-
min digestion, a single 
 
 
 
21-kD band was detected by
Western blotting (Fig. 2 a). This species corresponds to
the previously observed mature, fully-processed form of
VEGF-D (18), suggesting that plasmin can cleave both
Figure 2. Analysis of pro-
teolytic processing of VEGF-D by
plasmin with Western blotting.
(a) Analysis of 100 ng/lane human
VEGF-D-FULL-N-FLAG with
anti-VHD antibody after digestion
with 10, 1, 0.1, or 0 U/ml of
plasmin. (b)  2-antiplasmin inhibi-
tion of plasmin. Plasmin (1 U/ml;
130 nM) was incubated with a range
of   2-antiplasmin concentrations
before addition of VEGF-D-
FULL-N-FLAG and incubation
at 37 C for 1 h.  2-Antiplasmin/plasmin molar ratios are shown above the blot. (c) Analysis of 100 ng/lane mouse VEGF-D isoforms. Mouse
VEGF-D358 (358) and VEGF-D326 (326) were treated with 1 U/ml plasmin ( ) or remained undigested (–). Sizes of molecular mass markers in kD
are shown to the left of each panel.T
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the NH
 
2
 
- and COOH-terminal propeptides from the
VHD. NH
 
2
 
-terminal amino acid sequencing of this
 
 
 
21-kD species revealed two sequences, FAATFYDIE
and VIDEE, indicating that cleavage of the NH
 
2
 
-terminal
propeptide was occurring at two sites. FAATF (residues
89–93 of VEGF-D) represents the sequence identified as
the NH
 
2
 
 terminus of the predominant form of fully-pro-
cessed, mature VEGF-D purified from the conditioned
medium of 293EBNA cells (18). VIDEE (residues 101–
105 of VEGF-D) represents an NH
 
2
 
 terminus that is
located one residue toward the COOH terminus com-
pared with that of the other form of mature VEGF-D
(KVIDEE) detected in the medium of 293EBNA cells (18).
Therefore, plasmin cleaves the NH
 
2
 
-terminal propeptide
from the VHD at almost identical positions to those de-
scribed previously (18). In contrast to plasmin, the serine
proteases thrombin and tissue plasminogen activator were
unable to cleave the propeptides of human VEGF-D from
the VHD (unpublished data).
 
The plasmin used in this work was purified from human
plasma. To eliminate the possibility that the processing of
VEGF-D observed was due to a contaminating activity in the
plasmin preparation, 
 
 
 
2-antiplasmin, a specific inhibitor of
plasmin that forms an inactive 1:1 complex with this protease,
was incubated with the plasmin sample before digestion of
VEGF-D. Analysis of resulting digestion products demon-
strated complete inhibition of digestion by 
 
 
 
2-antiplasmin
when included at a fivefold molar excess to plasmin (Fig. 2 b).
Therefore, the observed proteolytic processing of VEGF-D by
the plasmin preparation used here was due to plasmin.
Full-length mouse VEGF-D exists as two isoforms,
VEGF-D
 
326
 
 and VEGF-D
 
358
 
, that differ in the COOH ter-
minus of the protein (19). Plasmin digestion of the mouse
VEGF-D isoforms was performed to analyze the effect of
the distinct COOH termini on proteolytic processing. Plas-
min treatment of both isoforms produced a 
 
 
 
21-kD species
containing the VHD, as for human VEGF-D, indicating
that this enzyme can fully process both isoforms (Fig. 2 c).
Figure 3. Mature growth factors
generated by plasmin bind and
cross-link receptors. (a) Binding to
soluble receptors. Receptor-Ig
fusion proteins containing the
extracellular domains of human
VEGFR-2 or VEGFR-3 were
conjugated to protein-A sepharose
and incubated with mature recom-
binant human VEGF-D as positive
control (Mature), PBS as negative
control, and undigested and plas-
min-digested full-length VEGF-D
(Undigested and Digested, respec-
tively).  (top) VEGFR-2 binding.
(bottom) VEGFR-3 binding.
Material bound to the receptor-Ig
proteins was analyzed by Western
blotting using an anti-VHD anti-
body. Plasmin-generated mature
VEGF-D ( 21 kD) is apparent.
Sizes of molecular mass standards
(kD) are shown to the left. (b and c)
Analysis of receptor binding and
cross-linking in BaF3 bioassays.
Ba/F3 cells expressing chimeric re-
ceptors containing the extracellular
domains of VEGFR-2 or VEGFR-3
and the cytoplasmic domain of
EpoR were treated with plasmin-
digested or undigested full-length
VEGF-D (b) or VEGF-C (c). (top)
VEGFR-2/EpoR bioassays. (bot-
tom) VEGFR-3/EpoR bioassays.
Controls were medium lacking
growth factor (Medium) or plasmin
digests lacking growth factor (Plas-
min). Values are the average of
duplicates   1 SD and are repre-
sentative of three experiments.
P-values comparing results of
plasmin-digested with undigested
material were calculated using
Student’s t test.T
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Plasmin Generates Bioactive VEGF-D and VEGF-C.
 
To establish if mature VEGF-D generated by plasmin
binds VEGFR-2 and VEGFR-3, we performed immuno-
precipitation studies using soluble receptor-Ig fusion pro-
teins containing the extracellular domains of VEGFR-2
or VEGFR-3 (Fig. 3 a). This revealed that the plasmin-
generated mature forms bound to both VEGFR-2 and
VEGFR-3 extracellular domains.
To compare the capacities of full-length and plasmin-gen-
erated mature VEGF-D to bind and cross-link receptors at the
cell surface, bioassays were used using Ba/F3 preB cells ex-
pressing chimeric receptors consisting of the extracellular do-
mains of human VEGFR-2 or VEGFR-3 and the transmem-
brane and cytoplasmic domains of the erythropoietin receptor
(EpoR; references 13, 20). These cell lines are IL-3–depen-
dent, however, signaling from the EpoR cytoplasmic domain,
which occurs when the extracellular domains of the chimeric
receptors are cross-linked by ligand, leads to cell survival and
proliferation in the absence of IL-3. These bioassays allow
comparison of receptor binding and cross-linking and were
used to define the receptor interactions of a range of VEGFR-2
and VEGFR-3 ligands (13, 20). Cells were incubated with
undigested or plasmin-digested VEGF-D in the absence of IL-3
and the proliferative response assessed by incorporation
of [
 
3
 
H]thymidine into DNA. Cells expressing either the
VEGFR-2 or VEGFR-3 chimeric receptors, which were ex-
posed to plasmin-digested VEGF-D, exhibited a much greater
response than those treated with undigested protein (Fig. 3 b).
Therefore, plasmin treatment generates mature forms of
VEGF-D that are much better able to bind and cross-link
VEGFR-2 and VEGFR-3 at the cell surface than full-length
material. Comparable results were observed with VEGF-C
(Fig. 3 c), indicating that plasmin activates both of the known
lymphangiogenic growth factors.
 
Discussion
 
In addition to activating the lymphangiogenic growth
factors VEGF-C and VEGF-D, plasmin modulates the ef-
fects of the angiogenic protein VEGF. Plasmin cleaves
some VEGF isoforms, releasing them from the extracellular
matrix or cell surface and, thus, making them available for
inducing angiogenesis (21, 22). In a porcine model of cuta-
neous wound healing, lymphatic vessels were observed to
appear concurrently with blood vessels (16), suggesting that
angiogenesis and lymphangiogenesis are coordinately regu-
lated. As VEGF-C and VEGF-D are localized on vascular
smooth muscle in adult tissues (23, 24) and VEGF levels are
elevated in cutaneous wounds (25), these growth factors
are available to coordinate angiogenesis and lymphangio-
genesis as a result of activation by plasmin during wound
healing. Furthermore, plasmin degrades fibrin clots and,
therefore, could integrate fibrinolysis and vessel formation
during wound healing. Examination of this hypothesis will
require (a) analysis of the relative activity of plasmin for
VEGF, VEGF-C, and VEGF-D and (b) correlation of local
plasmin levels with the timing of angiogenesis and lym-
phangiogenesis during wound healing.
Clinical analyses revealed that expression of VEGF-C or
VEGF-D in breast, ovarian, and colorectal cancer may be
an independent prognostic indicator of survival associated
with lymph node metastasis (8–11). Moreover, expression
of lymphangiogenic growth factors promoted metastatic
spread of tumor cells via the lymphatics in animal models
(6, 7, 26). Plasmin and other members of the fibrinolytic
system have also been associated with tumor growth and
metastasis (for review see reference 27) as shown in models
in which the fibrinolytic system was manipulated. For ex-
ample, overexpression of plasminogen activator inhibitor-2
inhibited the metastasis of a human melanoma cell line to
both the lymph nodes and the lung (28). Furthermore,
plasminogen-null mice displayed fewer regional lymph
node metastases than controls when transplanted with
Lewis lung carcinoma (29). A contributing factor underly-
ing these observations could be that down-regulation of
plasmin production leads to diminished tumor lymphan-
giogenesis and metastasis via the lymphatics. Therefore,
analysis of tumor lymphatics and lymphangiogenesis in
these animal models of cancer is required.
Studies in animal models showed that inhibiting the
VEGFR-3 signaling pathway blocked tumor lymphangio-
genesis and metastasis via the lymphatics (7, 30). Ap-
proaches included administration of an anti–VEGF-D anti-
body that blocked the binding of VEGF-D to VEGFR-2
and VEGFR-3 (7) or the soluble extracellular domain of
VEGFR-3 to sequester VEGF-C and VEGF-D (30). Alter-
natively, this pathway could be targeted at the level of
ligand activation using ligand-binding molecules that block
interaction with the processing proteases. The finding that
plasmin activates lymphangiogenic growth factors provides
an opportunity to screen for such inhibitors.
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